Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.6 GBX | 0.00% | -2.94% | +2.33% |
Apr. 18 | FTSE 100 up despite hawkish Fed rates outlook | AN |
Apr. 18 | AIM WINNERS & LOSERS: Surgical Innovations up as revenue jumps | AN |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's profit outlook over the next few years is a strong asset.
- The company is in a robust financial situation considering its net cash and margin position.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With a 2024 P/E ratio at 33.5 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Non-Gold Precious Metals & Minerals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.33% | 245M | C- | ||
-11.34% | 2.58B | A- | ||
-21.90% | 1.19B | - | - | |
+4.24% | 251M | - | ||
-8.55% | 226M | - | ||
+25.33% | 141M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- JLP Stock
- Ratings Jubilee Metals Group Plc